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Abstract
In adult mammals, the phenotype of half of all pain-sensing (nociceptive) sensory neurons is tonically modulated by growth
factors in the glial cell line-derived neurotrophic factor (GDNF) family that includes GDNF, artemin (ARTN) and neurturin
(NRTN). Each family member binds a distinct GFRa family co-receptor, such that GDNF, NRTN and ARTN bind GFRa1, -a2,
and -a3, respectively. Previous studies revealed transcriptional regulation of all three receptors in following axotomy,
possibly in response to changes in growth factor availability. Here, we examined changes in the expression of GFRa1-3 in
response to injury in vivo and in vitro. We found that after dissociation of adult sensory ganglia, up to 27% of neurons die
within 4 days (d) in culture and this can be prevented by nerve growth factor (NGF), GDNF and ARTN, but not NRTN.
Moreover, up-regulation of ATF3 (a marker of neuronal injury) in vitro could be prevented by NGF and ARTN, but not by
GDNF or NRTN. The lack of NRTN efficacy was correlated with rapid and near-complete loss of GFRa2 immunoreactivity. By
retrogradely-labeling cutaneous afferents in vivo prior to nerve cut, we demonstrated that GFRa2-positive neurons switch
phenotype following injury and begin to express GFRa3 as well as the capsaicin receptor, transient receptor potential
vanilloid 1(TRPV1), an important transducer of noxious stimuli. This switch was correlated with down-regulation of Runt-
related transcription factor 1 (Runx1), a transcription factor that controls expression of GFRa2 and TRPV1 during
development. These studies show that NRTN-responsive neurons are unique with respect to their plasticity and response to
injury, and suggest that Runx1 plays an ongoing modulatory role in the adult.
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Introduction
GDNF family ligands (GFL) are neurotrophic factors that
regulate the development and functional phenotype of peripheral
sensory neurons in the dorsal root ganglia (DRG). The GFL
receptor complex consists of Ret, a receptor tyrosine kinase, in
combination with a member of the GFRa family of glycopho-
sphatidylinositol-linked receptors (GFRa1-4). More recently,
neural cell adhesion molecule (NCAM) and integrin have been
implicated as potential co-receptors for GFL [1,2,3,4]. Following
peripheral nerve injury, successful regeneration requires a
program of gene expression that includes changes in growth
factor receptor expression [5,6,7]. In vivo studies of sensory neurons
following peripheral axotomy have found increases in the
percentage of neurons expressing GFRa1 and GFRa3 mRNA
(the receptors for GDNF and ARTN, respectively) and a decrease
in the percentage of GFRa2 (the receptor for NRTN) [8,9].
It has been proposed that injury-induced alterations in
peripheral growth factor expression lead to changes in GFRa
expression in sensory neurons [8], the inference being that GFL
can regulate the level of their cognate receptors. The majority of
GFRa1 and a2 neurons are non-peptidergic (i.e., do not express
the pro-inflammatory neuropeptides calcitonin gene-related pep-
tide (CGRP) or substance P (SP)) C-fibers, whereas virtually all
GFRa3-expressing neurons are peptidergic and 80% also express
TrkA, the tyrosine kinase receptor for nerve growth factor (NGF)
[10,11,12,13,14]. GFL protect against some of the pathological
effects of nerve injury, including loss of neuropeptide expression
and decreased conduction velocity [15]. In addition, both GDNF
and NGF have been shown to inhibit expression of the
transcription factor ATF3 [15,16], which is normally induced in
injured sensory neurons [17]. ATF3 is not only an effective marker
of injured neurons, but also a driver of peripheral nerve
regeneration [18].
Recent evidence indicates that, like GDNF and NGF, ARTN
can reverse some effects of nerve injury [19]. However, unlike
those factors, ARTN substantially improves functional recovery
after dorsal root injury as well as peripheral nerve injury, and this
recovery includes neurons that do not normally express the
receptor GFRa3 [20].
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The present study shows that NGF and ARTN regulate ATF3
expression and neuronal survival in vitro, whereas NRTN is
ineffective. In vivo, we demonstrate that in some cells the loss of
detectable GFRa2 is replaced by GFRa3 expression and that this
may be regulated by Runx1, a transcription factor critical for
differentiation of nociceptor subtypes. These changes have
important functional consequences for nociceptive transduction
in that neurons down-regulating GFRa2 subsequently begin to
express de novo functional TRPV1 channels. These results indicate
that injury-evoked changes in GFRa receptor expression alter the
efficacy of the GDNF family members, and may explain the
unexpected gain of function for ARTN and the loss of function for
NRTN during sensory neuron regeneration.
Results
Distribution of GFRa1-3-expressing sensory neurons in
vivo and 24 h in vitro
Initial experiments were designed to determine the proportion
of neurons expressing GFRa1-3 protein in situ (i.e., tissue sections
of DRG) and in dissociated neurons, to elucidate the extent to
which the phenotype of cultured neurons was representative of the
in vivo condition. Using recently validated GFRa1-3 antibodies
[13,21], we performed immunohistochemical staining on lumbar 4
(L4) DRG. Immunoreactivity for TRPV1 was also examined
because it is expressed in 95% of GFRa3 neurons, but in only a
minority of neurons labeled by the plant lectin IB4, that is
extensively colocalized with GFRa1 and a2 [15]. A large number
of cells immunoreactive for GFRa3 and TRPV1 were observed in
L4 DRG of naı¨ve mice (Fig. 1G, H, I), whereas IB4 was primarily
localized in GFRa2-positive (Fig. 1M, N, O) and small-diameter
GFRa1-positive neurons (Fig. 1J, K, L), confirming previous
studies [8,15,22].
Figure 2 shows the size distribution of GFRa1-, GFRa2- and
GFRa3- positive somata in L4 DRG. The size distribution of each
GFRa population was diverse; GFRa1-staining was seen in
neurons with both the largest and smallest somata, whereas most
GFRa2-positive neurons had somata with areas between 100–
200 mm2. The majority of GFRa3-positive neurons had somata
with areas below 150 mm2.
Table 1 shows the percentage of mouse neurons that express
GFRa1-, GFRa2- or GFRa3- immunoreactivity in situ and after
1 d in culture (the time point typically used for acute physiological
analysis of dissociated sensory neurons). Of all neurons identified
using NeuN in intact ganglia, 33.561.9% expressed GFRa1-
immunostaining, whereas 33.362.6% expressed GFRa2 and
24.860.8% expressed GFRa3, similar to what has been reported
in rat and mouse [8,14]. After 1 d in culture the percentages were
15.861.0, 2.160.6, and 43.962.9% for GFRa1, GFRa2,
GFRa3, respectively. The decreases in both GFRa1- and a2-
positive cells were statistically significant, as was the increase in
GFRa3 (all p values,0.05; t-test).
Extent of cell death in vitro and effects of growth factors
To determine whether the decrease in GFRa1 and GFRa2
expression was due to selective loss of specific cell populations after
dissociation, we counted the number of neurons at 6 hours (h) (the
time point at which all cells that survived the dissociation process
had attached to the coverslip), 1 d and 4 d after plating. Cells were
grown on coverslips containing a numbered grid so that the same
cells could be followed throughout the experiment. As shown in
Table 2, in the control condition (no exogenous growth factor)
85.3160.69% and 73.2263.27% of neurons survived at 1 d and
4 d after plating, respectively. The minimal loss of cells at 1 d
indicates that the decrease in the percent of cells expressing
GFRa1 or GFRa2 was not only due to selective cell death, but was
probably due to down-regulation of receptor expression. NGF
(50 ng/ml), GDNF (50 ng/ml) or ARTN (20 ng/ml) significantly
increased neuronal survival at both 1 and 4 d, whereas addition of
NRTN (50 ng/ml) did not prevent cell loss.
Expression of ATF3 is suppressed by NGF and ARTN but
not by NRTN
Because cell death did not appear to account for the dramatic
loss in the percent of GFRa2-expressing neurons, we examined
whether there were overt differences in the pattern of gene
expression in different neuronal populations following dissociation.
ATF3 is a transcription factor that has been shown previously to
be expressed in the vast majority of axotomized afferents [17], and
is thought to regulate the regeneration program [18] under the
control of growth factors ([16,23] (but see [24]). To test how
growth factors regulate ATF3 expression in different primary
afferent populations after dissociation in vitro, we applied NGF
(50 ng/ml), ARTN (20 ng/ml) or NRTN (50 ng/ml) at the time
of plating. 1 d after plating, 92% of DRG neurons (identified via
NeuN expression) expressed ATF3 immunoreactivity and this
widespread distribution was observed for up to 7 d in culture
without exogenous growth factors. To determine the impact of
NGF on ATF3 expression, cells were stained with an antibody to
CGRP, which has been shown previously to be expressed in 96%
of neurons expressing TrkA (the specific NGF receptor) [25].
Addition of NGF to the culture media eliminated ATF3 expression
in 96% of CGRP-immunoreactive neurons 1 and 4 d after culture
(Fig. 3). Similarly, application of ARTN eliminated ATF3
expression in 91% of GFRa3-immunoreactive neurons 1 and
4 d in culture (Fig. 4).
GFRa2 immunoreactivity could still be detected 6 h after
plating, and at this time point, ATF3 expression was seen in
virtually all GFRa2-expressing neurons (Fig. 5A–C). However,
GFRa2 expression was dramatically decreased after 1 d in culture
and was virtually absent by day 4 (Fig. 5D–I). Because the
percentage of both GFRa1- and GFRa2-positive cells was
decreased in vitro (Table 1), we examined the effect of NRTN
or GDNF on all sensory neurons identified by NeuN staining.
NRTN or GDNF application had no effect on the percentage of
cells expressing ATF3: 92% of all NeuN-positive cells expressed
ATF3 in the presence of either growth factor. This was true even
at 6 h after plating: over 95% of all neurons expressed ATF3 in
the presence or absence of GDNF or NRTN (data not shown).
We repeated these studies using IB4 labeling as a phenotypic
marker specifically for GFRa1 and GFRa2 neuronal populations.
In neurons from mice that lack GFRa2, the percentage of IB4-
positive cells is identical to that in cultures established from wild
type mice [26], indicating that IB4 binding is independent of
GFRa2 expression. Addition of NRTN, GDNF, or a combination
of NRTN and GDNF was not able to suppress the expression of
ATF3 in IB4-binding neurons: 84.661.4% of IB4-positive neurons
expressed ATF3 after 1 d in culture and this number was
unchanged following addition of NRTN or GDNF (86.961.4%
and 86.462.5%, respectively). After 4 d in culture 78.261.5% of
IB4-positive cells were immunoreactive for ATF3, whereas
77.961.6% and 79.062.3% were ATF3-positive despite the
addition of NRTN or GDNF. Addition of a combination of both
growth factors also had no effect on ATF3 expression at 1 d and
4 d (86.062.1% and 80.061.6% of IB4-positive neurons were
ATF3-positive at 1 and 4 d, respectively, after addition of both
GDNF and NRTN combined) (Table 3).
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To confirm whether the failure of NRTN to suppress ATF3
expression was a consequence of the loss of GFRa2, we added
exogenous soluble GFRa2 with NRTN to dissociated neurons.
This experiment was based on a previous study by Ernfors and
colleagues, who manipulated neurite outgrowth in sensory neuron
cultures using soluble GFRa1, indicating that addition of soluble
GFRa1 plus GDNF was able to engage downstream signaling
pathways [27]. We used this paradigm to determine if NRTN, in
the presence of soluble GFRa2, could block ATF3 expression.
GFRa2 (200 ng/ml) and NRTN (100 ng/ml) were added to
cultures at the same time that cells were plated. One day later,
86.762.1% IB4-positive neurons expressed ATF3 (similar results
were observed with 100 or 400 ng/ml soluble GFRa2; data not
shown). This percent was not different from the result without
GFRa2 (Table 3), indicating that NRTN does not regulate ATF3
expression even in the presence of GFRa2.
In vivo, axotomized GFRa2-expressing neurons
down-regulate GFRa2 and express GFRa3
Previous studies in rat indicated a near doubling in the number
of DRG neurons expressing mRNA for GFRa1 and GFRa3
following axotomy in vivo, such that over 66% of sciatic afferents
expressed GFRa1 and 66% expressed GFRa3 by day 14 post-
nerve cut [8]. Because the number of neurons expressing one or
both of these receptors exceeds 100%, this indicates that some cells
that did not previously express GFR -a1 or -a3, must now be
expressing these receptors. The observed down-regulation of
GFRa2 protein reported here and previously [8] makes these cells
likely candidates for switching receptor phenotype. To examine
the phenotype of GFRa2-positive neurons after peripheral nerve
injury in vivo, fluorescently-tagged IB4 (IB4-488), that is selectively
taken up by IB4-binding neurons, was injected subcutaneously into
the dorsal medial portion of the hindpaw prior to nerve
transection. When IB4-488 is injected into the hindpaw, it is
retrogradely transported through the saphenous nerve to cutane-
ous somata in the L2-3 DRG, where it labels both GFRa1 and
GFRa2-expressing neurons [15]. Three days after injection, IB4-
488 labeled a large number of neurons expressing GFRa2 (Fig. 6
A–D). No cells expressing GFRa3 were co-labeled with IB4-488
(Fig. 6 E–H). In contrast, one day following saphenous nerve
axotomy (4 d after IB4-488 skin injection), ATF3-immunoreactiv-
ity was seen in neurons retrogradely labeled with IB4 (Fig. 6 I–P).
By this time, the GFRa2 expression had already decreased to such
an extent in injured neurons that it was difficult to find neurons
that were GFRa2-positive and ATF3-positive, or GFRa2-positive
cells that were back-labeled with IB4-488 (Fig. 6 I–L). By day 6
post-axotomy, 38.9262.81% of IB4-488 back-labeled neurons
expressed GFRa3 (n= 4) (Fig. 6 U–X) indicating that a significant
proportion of neurons that previously expressed GFRa1 or
GFRa2, now expressed GFRa3.
To determine how gene expression was changing at the single
cell level, DRG cultures containing IB4-back-labeled neurons, 1
and 6 d post-axotomy, were used to harvest individual cells for
mRNA analysis. For these studies, 20 IB4-back-labeled neurons
per mouse were analyzed by RT-PCR. For each treatment (naı¨ve
(non-axotomized), 1 d post-axotomy, 6 d post-axotomy), 3 mice
Figure 1. Immunolabeling for GFRa1, 2 or 3 and TRPV1 and IB4 in L4 DRG. Most GFRa1- and GFRa2-positive neurons did not express TRPV1
(A–F). GFRa3-positive neurons expressed TRPV1 (arrow = double labeled cells) (G–I). GFRa2-positive (M–O) and small diameter GFRa1-positive
neurons (J–L) bind IB4 (arrows). Scale bar = 50 mm.
doi:10.1371/journal.pone.0028908.g001
Figure 2. Cell size distribution of PGP9.5-, GFRa1-, GFRa2- and GFRa3-positive neurons in L4-5 DRG. Neurons were sorted by their cell
area and the percent of neurons within each 50 mm bin were plotted. PGP9.5 staining was used to obtain the distribution for all sensory neurons.
Note that GFRa1-immunoreactivity was expressed in both small and large sized neurons. Most GFRa2-positive neurons had areas between 100–
250 mm2 whereas over 70% of GFRa3-positive neurons had areas of ,200 mm2.
doi:10.1371/journal.pone.0028908.g002
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were used (total of 60 cells/treatment). Consistent with the
immunostaining results, all IB4-labeled neurons expressed GFRa2
mRNA in naı¨ve DRG (Table 4), whereas GFRa1 and GFRa3
mRNA was identified in 8.060.5 (40%) and 5.760.3 (29%) cells
out of 20 IB4-back-labeled neurons/mouse, respectively. 1 and 6 d
after axotomy, all IB4-labeled neurons expressed ATF3 mRNA
and the number of neurons expressing GFRa2 mRNA decreased
to ,1/mouse (Table 4). No change was seen in the other genes
examined 1 d post axotomy, but by 6 d, the number of IB4-labeled
neurons expressing GFRa1 and GFRa3 increased significantly.
These changes in transcription mirror the changes in immunhis-
tochemical staining (Figure 6) and confirm previous studies in rat
[8]. However, GFRa1 mRNA distribution was stable at 1 d post-
axotomy, whereas we saw a decrease in staining for GFRa1 after
1 d in culture (Table 1). This difference could reflect that in the
immunohistochemical studies we analyzed all cells, not just IB4-
back-labeled cutaneous afferents. This difference could also reflect
a difference between protein and mRNA expression.
Figure 3. In vitro application of NGF decreased ATF3 expression in CGRP-positive neurons. In control conditions (no growth factor), more
than 90% of CGRP-positive neurons expressed ATF3 at 1 d (92.960.3%) (A–C; arrows) and 4 d (93.460.4%) (G–I; arrows) after plating. In NGF-treated
cultures, the percentage of CGRP-positive neurons that expressed ATF3 was significantly decreased at 1 d (3.860.3%) (D–F; arrowheads) and 4 d
(3.660.3%) (J–L; arrowheads). Scale bar = 50 mm. Two way ANOVA, p,0.01.
doi:10.1371/journal.pone.0028908.g003
Table 1. Percentage of neurons expressing GFRa1-, GFRa2-,
GFRa3- and TRPV1- immunoreactivity in DRG (in vivo) and 1 d
after culturing (in vitro).
GFRa1 GFRa2 GFRa3 TRPV1 IB4
in vivo (%) 33.561.9 33.362.6 24.860.8 30.361.5 28.360.8
in vitro
(%)(24 h)
15.861.0* 2.160.6%* 43.962.9* 36.360.6* 43.661.4*
In vivo, the percentage of neurons expressing GFRa1-3 was similar. In vitro,
GFRa2-positive cells were rarely seen 1 d after plating. The percentage of
GFRa1-positive cells was decreased whereas the percentage of GFRa3-positive
cells was increased. A small increase in the percentage of TRPV1-positive and
IB4-binding neurons also occurred (*p,0.05, t-test).
doi:10.1371/journal.pone.0028908.t001
Table 2. Sensory neuron survival in vitro.
Control NGF GDNF Artemin NRTN
6 h (%) 100 100 100 100 100
1 d (%) 85.3160.69 96.2461.13* 92.3862.06* 94.1262.09* 81.9565.23
4 d (%) 73.2263.27 89.5361.64* 87.7161.80* 88.4861.94* 76.1664.43
The number of NeuN-positive neurons 6 h after plating was designated as
100%. Without growth factors (Control), approximately 15% of neurons died
1 d after plating and 27% died by 4 d. Application of NGF, GDNF and ARTN
significantly increased neuron survival although NRTN was ineffective.
*p,0.05; Two way ANOVA, Dunnett’s post-hoc test.
doi:10.1371/journal.pone.0028908.t002
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Injured cutaneous afferents upregulate TRPV1
As shown in Figure 6, most IB4-488 back-labeled neurons from
naı¨ve mice expressed GFRa2. The single-cell RT-PCR data
indicated that 27% of these express TRPV1 mRNA (Table 4). Six
days after saphenous nerve axotomy, 77% of IB4-488 back-labeled
neurons expressed GFRa3 (Table 4). Because most GFRa3-positive
neurons express TRPV1 [13–14], we performed Ca2+ imaging to
determine the proportion of IB4-488 back-labeled neurons respond-
ing to capsaicin in naı¨ve and axotomized mice. In naı¨ve mice (n=3),
26.564.3% of IB4-488 back-labeled neurons responded to capsaicin
(1 mM) (similar to previous reports [28]). However, by 6 d after
saphenous nerve axotomy (n=3), this percentage had more than
doubled (68.567.5% (p,0.01; Fisher’s exact test)). This is slightly
lower than the percentage of IB4-488-back-labeled neurons that
expressed TRPV1 mRNA (78.3%; Table 4). Again, this might
reflect a difference between protein and mRNA and/or a difference
in the sensitivity of the two techniques (Ca2+ imaging and PCR). No
change occurred in the percentage of capsaicin responders that were
not back-labeled with IB4-488 (capsaicin responses in naı¨ve IB4-488-
negative neurons=43.665.5%: capsaicin responses in 6 d axoto-
mized IB4-488-negative neurons=45.160.3%) (Fig. 7). These data
suggest that most IB4-488 back-labeled neurons were axotomized and
that some of these neurons acquired TRPV1 function de novo,
following injury.
Changes in GFRa2 and Runx1 mRNA after axotomy
As noted above, previous studies in rat DRG showed changes in
mRNA expression for GFRa1-3 14 d following sciatic nerve
transection [8]. We confirmed these changes in mouse 6 d
following saphenous nerve transection using single cell RT-PCR
(Table 4) and on the whole DRG level following sciatic nerve
transection (Fig. 8B).
During development, Runx1 expression is required for the proper
differentiation of Ret-expressing neurons (including those co-express-
ing GFRa2) from the early TrkA-positive population, that contains
the majority of nociceptive neurons [29,30,31]. In the adult, Runx1 is
expressed in the majority of Ret/IB4-positive neurons including 92%
of the Mrgprd-positive neurons (a G protein-coupled receptor found
in 75% of IB4-positive neurons [32]), 79% of transient receptor
potential cation channel subfamily member M8 (TRPM8)-expressing
neurons (a cation channel gated by low temperatures and menthol)
and 15% of CGRP-expressing neurons [33,34]. In Runx1 knockout
mice, no cells are lost but the number of Ret-expressing neurons is
decreased by over 50%. However, the percentage of IB4-positive
neurons is normal, indicating that not all characteristics of the non-
peptidergic afferent population are regulated by Runx1 [34]. To test
whether Runx1 is required for GFRa2 expression, in situ hybridiza-
tion(ISH) was performed in DRG from WT and Runx1 knockout
mice. Figure 8A shows that in Runx1 knockout mice GFRa2
expression is greatly decreased, suggesting that GFRa2 is under
control of Runx1 expression. We also examined expression of Runx1
and GFRa1, 2, 3 after saphenous nerve axotomy. We found that
following axotomy, the decrease in Runx1 correlates with a decrease
in GFRa2, but not GFRa1 or GFRa3 (Fig. 8B), suggesting that
Runx1 continues to control GFRa2 expression in adulthood. ISH
confirmed that axotomized sciatic afferents (visualized by ATF3
staining) do not express Runx1 mRNA 5 d post-axotomy (Fig. 8C),
although Runx1 mRNA could be visualized in ATF3-negative
neurons. These data suggest that Runx1 expression is required to
maintain GFRa2 expression in the adult.
Discussion
The results presented here confirm previous studies showing
that sensory neuron populations defined by expression of GFRa1-
Figure 4. In vitro application of ARTN decreased ATF3 expression in GFRa3-positive neurons. In control conditions, most GFRa3-positive
neurons expressed ATF3 at 1 d (96.760.5%) (A–C, arrows) and 4 d (97.260.4%) (G–I; arrows) after plating. Addition of ARTN significantly decreased
the percentage of GFRa3-positive neurons that expressed ATF3 at 1 d (8.760.3%) (D–F; arrowheads) and 4 d (8.960.4%) (J–L; arrowheads). Scale
bar = 50 mm. Two way ANOVA, p,0.01.
doi:10.1371/journal.pone.0028908.g004
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3 respond differently following in vivo axotomy or dissociation in
vitro (a procedure that includes peripheral and central axotomy).
The present experiments extend those studies by demonstrating
that the GFRa2 population is unique in that following injury in vivo
and in vitro, these neurons rapidly down-regulate expression of
GFRa2 and begin to express a phenotype typical of the GFRa3
population, including expression of functional TRPV1 receptors.
Moreover, whereas in vitro phenotypic changes associated with
injury can be prevented in some sensory populations by growth
factors including NGF and ARTN, the changes seen in the
GFRa2 population cannot be reversed by addition of NRTN.
Interestingly, the loss of GFRa2 may be regulated by the
transcription factor Runx1, as Runx1 is required for the
developmental expression of GFRa2 and Runx1 is down-
regulated in vivo following nerve transection.
In many ways, growth factors in the GDNF family have unique
and complementary roles to those in the neurotrophin family
(NGF, BDNF, NT-3 or NT-4/5). Although there is a small
population of cells during early development that express Ret
(these appear to become primarily low threshold mechanorecep-
tors [30,35,36]), the majority of GFL-responsive neurons initially
express TrkA during early development and only begin to express
Ret and GFRa receptors after the period of embryonic
programmed cell death [30,36]. Transgenic ablation of NGF,
BDNF or NT-3 produces a significant reduction in the number of
sensory neurons present in adult DRG and trigeminal ganglia. In
contrast, genetic deletion of GFL or their receptors has a more
mild effect on DRG and trigeminal neurons, probably due to the
fact that expression of GFRa 1-3 and Ret is initiated in most
neurons later in development [37,38,39,40,41,42], after the period
of programmed cell death when up to half of all embryonic sensory
neurons undergo apoptosis [43]. In vitro, we observed a small (but
significant) increase in neuronal survival of adult neurons upon
addition of NGF, GDNF or ARTN but no effect for NRTN.
These effects were expected given the phenotype of GFL or GFRa
knockout mice. However, GFL have been reported to significantly
increase the survival of embryonic and neonatal neurons in vitro
[22]. The more dramatic survival effect of GFL on young sensory
neurons in vitro versus that seen in knockout mice may reflect the
response of young neurons to the injury sustained during
Figure 5. The percentage of GFRa2-positive neurons decreased after plating. 6 h after plating, 32% of neurons expressed GFRa2 (A, arrow)
and most GFRa2-positive neurons expressed ATF3 (B & C; arrows). 1 d and 4 d after plating, the expression of GFRa2 could not be detected (D, F) and
this was not reversed by application of NRTN or GDNF. Scale bar = 100 mm.
doi:10.1371/journal.pone.0028908.g005
Table 3. Application of NRTN and/or GDNF does not
suppress ATF3 expression in IB4-binding neurons.
Control NRTN GDNF GDNF+NRTN
1 d(%) 84.661.4 86.961.4 86.462.5 86.062.1
4 d(%) 78.261.5 77.961.6 79.062.3 80.061.6
1 d and 4 d after culturing, cells were stained with IB4 and ATF3. The
percentage of IB4-binding neurons that expressed ATF3 is shown. Compared
with control, application of NRTN, GDNF, or both, did not decrease ATF3
expression in IB4-binding neurons. Two-way ANOVA.
doi:10.1371/journal.pone.0028908.t003
Regulation of GFRa Receptors following Axotomy
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28908
dissociation; i.e., the process of culturing young neurons may
initiate death programs that can be reversed by addition of growth
factors. It should be noted that neuronal survival in the absence of
growth factors is low for embryonic and neonatal sensory neurons
(,20% for neurons younger than P15), whereas survival for adult
neurons is .70% 4 d after culturing ([22], current results), again
Figure 6. After saphenous nerve injury GFRa2-positive neurons down-regulated GFRa2 and expressed GFRa3. In naı¨ve mice, IB4-488-
back-labeled neurons were immunopositive for GFRa2 (A, B, D; arrows), but not GFRa3 (E, F, H; arrows). No ATF3 expression was seen following IB4-
488 injections in naı¨ve mice (C, G; arrows). One d after saphenous nerve lesion, IB4-488-back-labeled neurons expressed ATF3 (I, K, M, O; arrows),
however, GFRa2 expression in IB4-back-labeled neurons was decreased (I, J; arrows). GFRa3 expression was not seen in IB4-488-labeled neurons 1 d
post-transection (M, N, P; arrows). 6 d after saphenous nerve lesion, IB4-488-back-labeled neurons expressed ATF3 (Q, S, U,W; arrows) and GFRa3 (U,
V, X arrows), but not GFRa2 (Q, R, T; arrows). Scale bar = 50 mm.
doi:10.1371/journal.pone.0028908.g006
Table 4. The number of neurons expresses GFRa1-3, TRPV1 and ATF3 mRNA out of 20 IB4-labeled neurons in DRG after axotomy.
GFRa1 GFRa2 GFRa3 TRPV1 ATF3
Naı¨ve 8.060.5 (40%) 20 (100%) 5.760.3 (29%) 5.360.3 (27%) 0 (0%)
1 d 8.360.3 (42%) 0.360.3 (.02%) 6.060.5 (30%) 6.060.5 (30%) 20* (100%)
6 d 16.360.3* (82%) 0.360.3* (.02%) 15.360.5 (77%) 15.760.3* (79%) 20* (100%)
In naı¨ve (non-axotomized) mice, all IB4-back-labeled neurons expressed GFRa2 mRNA. However, GFRa2 mRNA expression was rarely detected 1 and 6 d post-axotomy.
The number of IB4-back-labeled neurons expressing GFRa1, GFRa3 and TRPV1 mRNA increased significantly 6 d post-axotomy. ATF3 mRNA expression was detected in
all IB4-back-labeled neurons 1 d after nerve transection and remained at this level for at least 6 d. (n = 3, *p,0.05, t-test).
doi:10.1371/journal.pone.0028908.t004
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suggesting that neonatal neurons are more vulnerable to injury-
induced cell death. Indeed, recent studies showed that BDNF is
required for survival of neonatal nociceptors in vivo [41].
GFRa2 is not the only sensory neuron growth factor receptor
that is decreased following injury; both p75 and TrkA are
somewhat decreased following peripheral nerve lesion, whereas
both TrkB and TrkC have been reported to increase [44,45].
However, the decrease observed in TrkA and p75 can be blocked
by exogenous NGF [45], whereas NRTN has no effect on GFRa2
expression, and thus, it seems as if GFRa2-expressing neurons are
hard-wired to down-regulate the expression of this receptor and to
lose the ability to respond to NRTN. One possible mechanism for
this difference is that GFRa2 may continue in adulthood to be
dependent on the expression of Runx1, which regulates its
expression during development. Thus, when Runx1 is decreased
following axotomy, GFRa2 is also decreased. During embryogen-
esis, TrkA is co-expressed with Runx1 and appears to be regulated
by Runx1 [29,31,34,46]. However, during late development
Runx1 is down-regulated in TrkA-expressing neurons, presumably
freeing TrkA from regulation by this transcription factor. The
observed up-regulation of GFRa1 and GFRa3 indicate that either
these receptors are not regulated by Runx1 in the adult or that
Runx1 is acting as a repressor, an action it exerts during
development ([8,47], present results).
In culture, only NGF and ARTN, but not NRTN or GDNF,
can block upregulation of ATF3. Interestingly, in mouse, 80% of
neurons that express GFRa3 also express TrkA [14] so it is not
clear if the ability to regulate ATF3 is specific to the population of
cells expressing these two receptors or if downstream signaling is
different when Ret interacts with GFRa3 compared to Ret
activation in combination with GFRa1 or GFRa2. (However, it
should be noted that a population of GFRa3-expressing neurons
may not express Ret [19]). That this is not the case is suggested by
the studies of Averill et al [16] that showed both NGF and GDNF
could prevent the upregulation of ATF3 in adult rat in vivo when
applied intrathecally for two weeks. These results indicate that
long-term activation of Ret via GDNF can regulate ATF3. Why
this does not happen in vitro during the short time course examined
here could be due to numerous differences in the experimental
paradigm including species, the effect of culturing and the time
course of the two experiments.
ATF3 was uniformly upregulated in all injured neurons
examined regardless of the changes in GFRa receptor expression
in vivo or in vitro. This suggests the importance of ATF3 to
regeneration [18]. GFRa2 is expressed in the majority of
cutaneous afferents (ca. 70%; [48,49]) and these correspond
physiologically to polymodal C-fibers (CPM) [50,51]. These fibers
appear to regenerate at the same rate as other C-fibers [52] and
thus, expression of GFRa2 does not appear to be a prerequisite for
regeneration. Interestingly, analysis of GFRa2 knockout mice
indicates that these neurons fail to innervate the epidermis in the
Figure 7. The percentage of IB4-488 labeled neurons respond-
ing to capsaicin was increased 6 d after nerve axotomy. In naı¨ve
mice, 26.564.3% of IB4-488 back-labeled neurons (IB4+) responded to
capsaicin. The percentage increased to 68.567.5% 6 d after axotomy. In
neurons that were not labeled by IB4-488 (IB4-), the percentage of
capsaicin responders was not different before and after axotomy.
Fisher’s exact test, *p,0.01.
doi:10.1371/journal.pone.0028908.g007
Figure 8. GFRa2 expression was dramatically decreased in Runx1 knockout mice. ISH for GFRa2 in WT (A) and Runx1 knock out (A/) mouse
DRG showed significant reduction of GFRa2 in Runx12/2 ganglia. B) Fold change of GFRa1-3 and Runx1 mRNA following sciatic nerve transection.
GFRa2 and Runx1 decreased concurrently. GFRa1 and GFRa3 increased at 6 d post transection confirming previous rat ISH studies. *p,0.05; t-test. C)
Five days after sciatic nerve axotomy, Runx1 expression decreased in ipsilateral DRG (C/) relative to contralateral DRG (C). Runx1 expression (green)
was absent in ATF3-positive neurons in ipsilateral DRG (C//). Scale bar = 50 mm.
doi:10.1371/journal.pone.0028908.g008
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absence of NRTN/GFRa2 signaling during early postnatal
development [48].
Previous studies by Stucky and others indicate that GFRa2
expression is required for detection of noxious heat in dissociated
IB4-binding neurons [26]. Because only a quarter of these neurons
express TRPV1 mRNA and all have normal heat sensitivity in
TRPV12/2 mice [51], the majority of these neurons possess the
ability to transduce heat stimuli independently of TRPV1.
However, following axotomy, the data presented here indicate
that some of these neurons begin to express TRPV1. This could
theoretically explain the increased thermal sensitivity of C-fiber
polymodal nociceptors to noxious thermal stimulation seen after
regeneration [52]. That IB4-positive neurons are capable of
expressing TRPV1 in culture following inflammation has been
reported [28], although other laboratories have seen no change in
cultured inflamed cutaneous afferents [53]. Thus, the ability of
inflammation to induce de novo TRPV1 expression in cutaneous
afferents remains controversial.
In summary, the studies conducted here indicate that GFRa2-
expressing neurons are unique relative to other populations of
sensory afferents identified based on growth factor receptor
expression. GFRa2 is rapidly and dramatically down-regulated
in response to injury in vitro and in vivo and these neurons appear to
switch phenotype so that they can respond to a related growth
factor (ARTN) and express TRPV1, a channel not normally seen
in these neurons. These changes have obvious functional
implications for the development of cutaneous hypersensitivity
following injury. Identification of the signaling changes that lead to
these alterations could provide new and useful therapeutic targets.
Materials and Methods
Animals
Experiments were conducted using young adult (6–8 weeks)
male C57BL/6 mice (Jackson Lab). All animals were housed in
group-cages, maintained on a 12 h light/dark cycle with a
temperature-controlled environment, and given food and water
ad libitum. All studies were performed in accordance with the
guidelines of the Institutional Animal Care and Use Committee at
the University of Pittsburgh and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Cell culture
Primary cultures were prepared as previously described [54].
Briefly, mice were given an overdose of avertin anesthetic and
perfused transcardially with 4uC Ca2+/Mg2+ free Hank’s balanced
salt solution (HBSS). DRG were rapidly dissected and enzymatically
treated with papain followed by collagenase to facilitate dissociation.
DRG were then triturated in 0.5 ml F12 growth media (Invitrogen)
containing 10% fetal calf serum and antibiotics (penicillin/
streptomycin, 50 U/mL), and plated on laminin/poly-d-lysine
coated dishes with a density of 1.856105. Plated cells were fed 2 h
later with F12 growth medium containing 10% FCS (fetal calf
serum) and antibiotics (penicillin/streptomycin, 50 U/ml). The
growth factors were added to the medium at following concentra-
tions: NGF (50 ng/ml), GDNF (50 ng/ml), ARTN (20 ng/ml),
NRTN (50 ng/ml). For the experiment with application of both
NRTN and GFRa2, three different sets of concentrations were used:
NRTN (50 ng/ml), GFRa2 (100 ng/ml); NRTN (100 ng/ml),
GFRa2 (200 ng/ml); NRTN (200 ng/ml), GFRa2 (400 ng/ml).
Animal Surgery
All surgical procedures were performed under sterile conditions
in a designated animal surgery area. Anesthesia was initiated by
inhaled 4% isoflurane and maintained with inhaled 2% isoflurane.
To assess changes in mRNA expression for GFRa1-3 and Runx1
induced by peripheral nerve axotomy, we performed sciatic and
saphenous nerve axotomy. For sciatic nerve axotomy, the left hind
leg was shaved, the skin was sterilized with betadine, the left sciatic
nerve was exposed at the level of the head of the femur, transected
and the wound was closed with wound clips. Saphenous nerve
axotomy was performed on the right leg. A 5–6 mm incision was
made in the skin at the mid-thigh level and the saphenous nerve
was gently exposed and transected using fine scissors. Wounds
were closed using 7.0 prolene sutures. At each time point studied,
mice were given an overdose of avertin anesthetic, perfused with
saline (followed in some cases by 4% paraformaldehyde) and DRG
L4-5 (source of sciatic nerve primary afferents) from the left side or
DRG L2-3 (source of saphenous nerve primary afferents) from the
right side were collected.
To back-label non-peptidergic, IB4-binding, cutaneous afferents
(the majority of which express GFRa2), 10 ml of 2 mg/ml IB4-488
was injected subcutaneously into dorsal medial side of both
hindpaws for retrograde transport via the saphenous nerve to L2-3
DRG. Three days later, the saphenous nerve was transected.
These mice were used to identify changes in gene and protein
expression in the IB4-binding afferents following nerve transection.
Calcium imaging and immunocytochemical staining and single
cell RT-PCR were carried out 1–6 d after nerve transection.
To determine whether saphenous nerve axotomy had an effect
on retrograde transport of IB4-488, we compared the percentage
of neurons labeled by IB4-488 in two groups of mice. One group of
mice had IB4-488 injected and L2-3 DRG were collected 9 d later.
The second group had IB4-488 injected, followed by saphenous
nerve axotomy 3 d later. 6 d following axotomy, L2-3 DRG were
collected and analyzed for the percent labeled by IB4-488. There
was no difference in the percent labeling, suggesting that axotomy
had no effect on IB4-488 transport during the time points used for
these studies. To determine if nerve cut in vivo had any effect on
IB4-binding (i.e., if nerve transection decreased the expression of
the ganglioside that bind the IB4 lectin), some mice were back-
labeled with IB4-488 prior to nerve cut, then allowed to survive for
6 more days prior to culture and stained with fluorescently tagged
IB4-647. All of the IB4-488-back-labeled cells were stained with
IB4-647, indicating that despite being transected 6 d prior to
culturing, all cells still expressed the gangliosides that bind IB4.
Immunohistochemistry
For in vitro studies, coverslips containing dissociated cells were
fixed in 4% paraformaldehyde for 10 min, washed in 0.1 M
phosphate-buffered saline (PBS), and then incubated in blocking
solution (2% normal horse serum, 0.2% Triton X-100 in PBS,
pH 7.4) for 60 min. Coverslips were then incubated in primary
antibodies diluted in blocking solution at 4uC overnight. Rabbit
anti-TRPV1 (1:1000 Neuromics), goat anti-GFRa1 (1:500 R&D
Biosystems), goat anti-GFRa2 (1:500 R&D Biosystems), goat anti-
GFRa3 (1:100 R&D Biosystems), mouse anti-NeuN (1:100
Chemicon), rabbit anti-CGRP (1:1000 Chemicon), rabbit anti-
ATF3 (1:200 Santa Cruz Biotechnology), rabbit anti-PGP9.5
(1:100, Ultraclone) were used. Binding of primary antibodies was
visualized with donkey anti-rabbit, donkey anti-goat or donkey
anti-mouse secondary antibodies conjugated to Cy3 or Cy2
(1:1000; Jackson Immunoresearch). Coverslips were mounted in
DPX on slides and photographed. Images were captured using
Leica Application Suite (LAS) software and LEICA DM 4000B
microscope.
For immunohistochemistry of IB4-488 back-labeled DRG, mice
received an overdose of avertin anesthetic followed by transcardial
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perfusion with 4% paraformaldehyde. DRG were collected,
cryoprotected in 30% sucrose, embedded in OCT mounting
medium, cut at 20 mm on a cryostat and mounted on Superfrost
microscope slides. Immunolabeling was performed as described
above.
To perform double-labeling with CGRP and ATF3 antibodies
which are generated from rabbit antiserum, we used Fab
secondary antibodies as previously described [55]. Coverslips
were incubated with blocking solution at room temperature for
1 hr, incubated in CGRP antibody at 4uC overnight, washed with
PBS, then incubated with goat anti-rabbit Fab fragments (1:50;
Jackson Immunoresearch) at 4uC overnight. CGRP staining was
visualized using donkey anti-goat Cy3 antibody. Coverslips were
then incubated with ATF3 antibody at 4uC for overnight and
ATF3 binding was visualized with donkey using anti-rabbit Cy2
antibody.
The percentage of GFRa-positive cells (expressed as a percent
of the total number of NeuN-positive cells) was calculated in L4
DRG from three mice using systematic random sampling as
described previously [56]. A total of 200 NeuN-positive cells per
animal was assessed. Cellular profiles with a clearly defined
nucleus with robust immunoreactivity (at least 5 standard
deviations above background intensity) were considered positive.
Images taken with one wavelength of fluorescence were scored and
then overlaid with images of the second wavelength, allowing
scoring of single- and double-labeled cells.
Cell size distribution
NIH ImageJ was used to measure the area of neurons. DRG
sections were labeled with antibodies to PGP9.5 (a pan-neuronal
marker), GFRa1, GFRa2 or GFRa3 separately. DRG from three
animals were analyzed and 200 positively-stained neurons for each
marker from each animal were measured.
Analysis of in vitro cell survival
To determine the amount of cell death over time in culture and
the effect of growth factors on survival, neurons were plated on
gridded, numbered coverslips. Eight squares from each coverslip
were randomly selected and the number of neurons in each square
was counted at 6 h, 1 d and 4 dafter plating. Neurons were grown in
standard media with one of the following: NGF (50 ng/ml), GDNF
(50 ng/ml), NRTN (50 ng/ml), ARTN (20 ng/ml) or without
growth factor. Coverslips from six mice were analyzed for each
condition. The cell number at 6 h in each condition was normalized
as 100%. Data were analyzed using SigmaStat software. Significance
was tested using a two-way ANOVA, and Dunnett’s posthoc test.
RNA isolation and real-time RT-PCR
RNeasy Mini kits (Qiagen) were used to isolate total mRNA.
RNA (1 mg) was DNased (Invitrogen) to remove genomic DNA,
and then reverse-transcribed using Superscript II reverse tran-
scriptase (RT) (Invitrogen). Real-time RT-PCR was performed as
described previously [56] to determine the extent of expression of
growth factor receptors in sensory neurons after sciatic nerve
lesion. SYBR Green-labeled PCR amplification was performed
using an Applied Biosystems 5700 real-time thermal cycler (Foster
City, CA) controlled by Prism 7000 SDS software (Applied
Biosystems). All samples were run in triplicate, and control
reactions were run without template as negative controls with
every amplification run. The relative fluorescence of SYBR Green
bound to double-stranded DNA was compared with a passive
reference for every cycle. Threshold cycle (Ct) values, the cycle
number in which SYBR Green fluorescence rose above back-
ground, were recorded as a measure of initial template
concentration. Relative fold changes in RNA levels were
calculated by the DDCt method using GAPDH as a reference
standard: Ct values from triplicate samples were averaged and
then subtracted from the reference standard, yielding DCt. The
difference between the DCt of the experimental and control
groups were then calculated (DDCt). The relative fold change was
determined as 22DDCt. Statistical significance was determined by t-
test. Primers optimized for real-time RT-PCR were designed using
Oligo software (Molecular Biology Insights) and shown inTable 5.
Table 5 also showed the melting temperature for each primer.
The annealing temperature was 60uC.
Calcium imaging
Fourteen to seventeen hours after dissociation, cells were loaded
with Ca2+ indicator by incubation in HBSS containing 5 mg/ml
bovine serum albumin and 2 mM of the acetoxymethyl ester of
fura-2 (Invitrogen) for 30 min at 37uC. Coverslips were placed on
an Olympus microscope stage mount with 30uC HBSS buffer
flowing at 5 ml/min. Firmly attached cells with IB4-488 labeling
were chosen and identified as regions of interest in the software
(Simple PCI; C-Imaging, Compix Imaging Systems). Emission
data at 340 and 380 nm were collected at 1 Hz, and the change in
the 340/380 ratio analyzed. Ca2+ transients were examined in
response to brief application of 1 mM capsaicin (Sigma) delivered
onto neurons using a multi-barrel drug delivery system.
In situ hybridization
The protocol for GFRa2 ISH was reported previously [34].
Briefly, an ISH probe for GFRa2 was amplified using a nested
PCR strategy with gene-specific sets of PCR primers and cDNA
templates prepared from P0 mouse whole brain. The probe was
labeled with digoxigenin (Roche). To test the dependence of
GFRa2 expression on the presence of functional Runx1, P30
Runx1F/F and Runx1F/F;Wnt1-cre mice were perfused with 4%
paraformaldehyde. Lumbar DRG were dissected, post-fixed for 1–
2 h, cryoprotected overnight in 20% sucrose and cut at a thickness
Table 5. Primers (sequences and melting temperatures) used for real-time RT-PCR assays.
Gene Forward Primer (59–39) Tm(6C) Reverse Primer (59–39) Tm(6C)
GAPDH ATGTGTCCGTCGTGGATCTGA 58.1 ATGCCTGCTTCACCACCTTCTT 58.6
GFRa1 GTGTGCAGATGCTGTGGACTAG 57.6 TTCAGTGCTTCACACGCACTTG 58.5
GFRa2 TGACGGAGGGTGAGGAGTTCT 59.1 GAGAGGCGGGAGGTCACAG 58.7
GFRa3 CTTGGTGACTACGAGTTGGATGTC 57.7 AGATTCATTTTCCAGGGTTTGC 54
Runx1 TTTCAAGGTACTCCTGCCTGA 55.2 CAGTGAGAAGGACCAGAGACT 55.3
doi:10.1371/journal.pone.0028908.t005
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of 12 mm. Slides containing tissue sections with both genotypes
were pretreated with proteinase K and TEA/acetic anhydride
before being incubated overnight at 64uC with the GFRa2 probe.
Reaction with the NBT/BCIP substrate (Roche) was allowed to
proceed overnight. For experiments in which Runx1 ISH was
combined with ATF3 immunolabeling, L3-5 DRGs were collected
5 d after sciatic axotomy (see above). Ganglia were first stained
with anti- antibody (rabbit 1:1000, Santa Cruz) and photographed,
followed by development for Runx1 ISH using fluorescently-
tagged tagged nucleotides [34].
Single Cell RT-PCR
All mice were injected in footpad skin with IB4-488 as described
above (9 d prior to sacrifice). Two to four hours after dissociation
and culture, IB4-back-labeled DRG neurons were collected under
fluorescence microscope (Leica) with large-bore (,50 mm) glass
pipettes and expelled into microcentrifuge tubes containing reverse
transcriptase mix (Invitrogen). For each experiment, negative
controls consisted of omitting RT or using a cell-free bath aspirate
as template. The first-strand cDNA was used as template in a PCR
reaction containing 16GoTaq reaction buffer (Promega); primer
sequences are listed in Table 6. Each initial PCR product served
as template in a subsequent PCR using a nested or semi-nested
primer pair, the products of which were electrophoresed on 2%
agorose-ethidium bromide gels and photographed. Only samples
producing detectable amplification of positive control housekeep-
ing gene (GAPDH) were analyzed.
Statistical analysis
All the detail of statistical analysis is listed at the end of figure
and table legends.
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